AIVITA Biomedical Announces New Discovery with Applications to Regenerative Medicine, Skin Aging and Hair Growth
Company discovers new methods of capturing and using short-range intercellular signals to stimulate a healthy cell environment
IRVINE, Calif. September 19, 2017 – AIVITA Biomedical today announced the discovery of a new method for capturing and using intercellular signaling molecules to induce the reactivation of stem cell niches. The implication of this discovery is the ability to preserve or restore the microenvironment in which stem cells can self-renew and promote the healthy growth and maintenance of human tissue. AIVITA is already applying the technology in skin care, where it can be used to effectively recreate the microenvironment in which young, healthy skin thrives. The discovery is the result of its ongoing research into cell biology and aging, and is the subject of an international patent application the Company has submitted to the United States Patent and Trademark Office (USPTO).
“The applications of this discovery in anti-aging skin care are very exciting, but the technology’s potential extends well beyond the skin,” said Dr. Gabriel Nistor, Chief Science Officer of AIVITA. “Such a technology can also be applied to hair loss and thinning associated with a diminished stem cell niche.”
Dr. Nistor added that the ability to understand and interact with short range inter-cell communications exceeds the potential of current hormone and growth factor technologies.
The Company is applying this technology in a new cosmetic line that is currently undergoing clinical testing. A version of the technology using different cell-to-cell signals is also being developed for hair regeneration.
“Our research team continues to make advancements which harness the natural functions of stem cells for remarkable therapeutic benefit,” said Dr. Hans Keirstead, CEO of AIVITA. “The potential this technology has for skin care, hair care, and regenerative medicine should get people excited. We certainly are.”
About AIVITA Biomedical
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient and economical manufacturing systems which support its commercial line of skin care products and therapeutic pipeline. Sales of AIVITA’s skin care products support its clinical development program, including a platform cancer immunotherapy.